ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "immunology"

  • Abstract Number: 0010 • ACR Convergence 2023

    A Potential Mechanism for Major Adverse Cardiac Events Associated with JAK Inhibitors: JAK Inhibitor Withdrawal Causes Urokinase Release by Primed STAT Signaling

    Sara McCoy1, Ilya Gurevic2 and jacques Galipeau2, 1University of Wisconsin School of Medicine and Public Health, Middleton, WI, 2University of Wisconsin, Madison, WI

    Background/Purpose: Sjögren’s Disease (SjD) has high glandular IFNg levels, associated with disease activity and lymphoma risk. We showed that IFNg-stimulated minor salivary gland (SG)-mesenchymal stromal…
  • Abstract Number: 0092 • ACR Convergence 2023

    Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion

    Michael Tang1, Zoya Qaiyum2, Melissa Lim1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Sustained chronic inflammation in the spine and of the sacroiliac joints is a key feature in Ankylosing Spondylitis (AS). A central role of CTL…
  • Abstract Number: 0838 • ACR Convergence 2023

    Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections

    Russell Ross1, Vibeke Strand2, Roel Querubin3, John Goldman4, Richard Leff5, Alexis Melson1, Pei-Ling Roerig6 and Alan Smith7, 1Sorrento Therapeutics, Atlanta, GA, 2Stanford University, Portola Valley, CA, 3Marietta Rheumatology Associates, Marietta, GA, 4Northside Hospital, Atlanta, GA, 5Kezar Life Sciences, Chadds Ford, PA, 64P Therapeutics, Orlando, FL, 74P Therapeutics, Atlanta, GA

    Background/Purpose: The lymphatic system serves as a conduit for transporting immune cells and inflammatory molecules present in arthritic joints to lymph nodes (LN), playing a…
  • Abstract Number: 1637 • ACR Convergence 2023

    IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity

    Helena Achten1, Liselotte Deroo2, Kristel De Boeck3, Matthias Jarlborg1, Tine Decruy1, Joke Deprez1, Emilie Dumas1, Dirk Elewaut4 and isabelle peene5, 1Ghent University, Ghent, Belgium, 2Ghent University, Gent, Belgium, 3Ghent University Hospital, Ghent, Belgium, 4Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 5University Hospital Ghent, Ghent, Belgium

    Background/Purpose: Loss of galactose and sialic acid structures attached to the IgG-Fc-fragment switches the antibody effector function from anti-inflammatory to pro-inflammatory1. This study investigated the…
  • Abstract Number: 2184 • ACR Convergence 2023

    Development of Salivary Gland Organoids to Study Sjögren Syndrome

    Loïc Meudec1, Negaar Goudarzi2, Juliette Pascaud3, Fanny Jaulin2, Xavier Mariette4 and Gaetane Nocturne5, 1CHU Kremlin-Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France, 2INSERM UMR 981, Institut Gustave Roussy, Villejuif, France, Villejuif, France, 3Center for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR 1184, FHU CARE, Université Paris-Saclay, Le Kremlin-Bicêtre, France, 4Université Paris-Saclay, Le Kremlin-Bicêtre, France, 5APHP, Le Kremlin-Bicêtre, France

    Background/Purpose: Sjögren disease (Sjo) is an autoimmune disease characterized by the infiltration of exocrine glands by immune cells, especially salivary glands (SG). SG epithelial cells…
  • Abstract Number: 0022 • ACR Convergence 2023

    Validation of a Transcriptomic-Based Machine Learning Model to Establish the Endotype of SLE Patients

    Erika Hubbard1, Prathyusha Bachali2, Kathryn Kingsmore Allison1, Amrie Grammer1 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Redmond, WA

    Background/Purpose: We previously developed a novel machine learning (ML) pipeline leveraging analysis of gene expression data to identify subsets of SLE patients with common molecular…
  • Abstract Number: 0094 • ACR Convergence 2023

    Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium

    Anna Helena Jonsson1, Carlos Donado2, Erin Theisen2, Dominique Jones1, Aparna Nathan3, Fan Zhang4, Accelerating Medicines Partnership (AMP): RA/SLE1, Soumya Raychaudhuri1 and Michael Brenner2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Harvard Medical School, Boston, MA, 4University of Colorado, Aurora, CO

    Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. While most research has focused on CD4+ T cells, we have found that CD8+…
  • Abstract Number: 0900 • ACR Convergence 2023

    Complement Deposition on Extracellular Mitochondria Induces Platelet Activation in Vitro

    Marina Barguil Macedo and Christian Lood, University of Washington, Seattle, WA

    Background/Purpose: Mitochondria are extruded upon cell death and platelet activation, being elevated in several inflammatory conditions, including systemic lupus erythematosus (SLE). Mitochondria are immunogenic, with…
  • Abstract Number: 1651 • ACR Convergence 2023

    Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

    Esther Vicente Rabaneda1, Pedro Martínez-Fleta2, Ana Triguero-Martínez2, Emilia Roy3, Miren Uriarte-Ecenarro4, Francisco Gutiérrez-Rodríguez4, Patricia Quiroga4, Ana Romero4, Nuria Montes2, Laura Esparcia Pinedo2, María Aranzazu Alfranca2, Rosario Garcia-Vicuna5, Francisco Sánchez-Madrid2, Isidoro González-Álvaro4 and Santos Castañeda5, 1Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 2Division of Immunology, Hospital Universitario de La Princesa, Madrid, Spain, 3Division of Internal Medicine, Hospital Universitario de La Princesa, Madrid, Spain, 4Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 5Hospital Universitario de la Princesa, Madrid, Spain

    Background/Purpose: Previous published works have raised the concern that methotrexate (MTX) might have a negative effect on immune response upon vaccine administration. At the beginning…
  • Abstract Number: 2191 • ACR Convergence 2023

    Efficacy of anti-CD38 Treatment with Daratumumab in Two Cases of Refractory and Severe Sjogren Disease

    Gaetane Nocturne1, Mathilde di Filippo2, Oriane Marmontel2, Pascale Chretien1, Roman Krzysiek1, François Lifermann3, Nawal Rahal1, Rakiba Belkhir4, Philippe Moulin2 and Xavier Mariette5, 1APHP, Le Kremlin-Bicêtre, France, 2Hospices Civils de Lyon, Lyon, France, 3Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France, 4Rheumatology Department, Université Paris-Saclay, INSERM U1184, Hôpital Bicêtre, APHP, FHU CARE, Le Kremlin-Bicêtre, France, 5Université Paris-Saclay, Le Kremlin-Bicêtre, France

    Background/Purpose: Sjögren's disease (Sjo) is a systemic autoimmune disease. In 80% of the patients, Sjo is responsible for dryness, fatigue, and joint pain. In 10%…
  • Abstract Number: 0032 • ACR Convergence 2023

    Quantification of the Escape from X Chromosome Inactivation with the Million Cell-scale Human Blood Single-cell RNA-seq Datasets Reveals Heterogeneity of Escape Across Immune Cells and Escape in the Autoimmune Disease Conditions

    Yoshihiko Tomofuji1, Ryuya Edahiro1, Yuya Shirai1, Kyuto Sonehara2, Qingbo Wang1, Atsushi Kumanogoh1 and Yukinori Okada3, 1Osaka University, Suita, Japan, 2University of Tokyo, Tokyo, Japan, 3University of Tokyo / Osaka University / RIKEN, Tokyo, Japan

    Background/Purpose: Understanding the differences in the immune system between sexes is important to elucidate the pathogenesis of autoimmune diseases which are more prevalent in females…
  • Abstract Number: 0105 • ACR Convergence 2023

    Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis

    Yin Long1, Jiuliang zhao2, Mengtao Li2 and Xiaofeng Zeng2, 1Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, 2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by the presence of pathogenic autoantibodies. The key immune cell subsets change in PAPS patients…
  • Abstract Number: 0906 • ACR Convergence 2023

    Paired Autoantibody Specificities from Serum and Immune Complexes Do Not Fully Explain the Circulating Immune Complex Load in Systemic Lupus Erythematosus: A Study on 530 Patients

    Enrico Fuzzi1, Anna Svanqvist2, Christine Westerberg2, Agneta Zickert3, Iva Gunnarsson4, Johan Rönnelid2 and Elisabet Svenungsson5, 1Karolinska University Hospital, Stockholm, Sweden, 2Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden, 3Karolinska University Hospital, Stockholm, Sweden, Stocksund, Sweden, 4Karolinska Institutet, Stockholm, Sweden, 5Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypical autoimmune disease where autoantibody production and immune complex (IC) formation play a key role. Which antibodies contribute…
  • Abstract Number: 1676 • ACR Convergence 2023

    Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology

    Paula David1, Thomas Macleod2, Yu Shi3, Payal Ganguly1, Cedric Duval3, Mark Harland1, Chi Wong1, Benazir Saleem4 and Dennis McGonagle5, 1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, 2University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 3Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 4Leeds Teaching Hospitals NHS Trust, Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, 5Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) patients treated with Janus Kinase inhibitors (JAKi) have reportedly higher venous thromboembolism (VTE) risk and atherosclerotic-related complications including myocardial infarction (1).Although…
  • Abstract Number: 2242 • ACR Convergence 2023

    Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes

    M. Elaine Husni1, Vinod Chandran2, Jeffrey Lisse3, Rebecca Bolce3, Carlos Diaz3, Baojin Zhu3, Elaine Lui4 and Laura Coates5, 1Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, 3Eli Lilly and Company, Indianapolis, IN, 4Brightech International, An Everest Clinical Research Company, Somerset, NJ, 5University of Oxford, Oxford, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic and progressive disease characterized by high rates of early joint erosions, which have been associated with impaired quality…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 33
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology